Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC Drug Service.

Abstract	CDC has recently reviewed data on the reported incidence in the United States of Plasmodium falciparum malaria and has evaluated available information on the effective management of severe life-threatening infections. As a result of this review, CDC has concluded that the therapeutic drug of choice in the United States for persons with complicated P. falciparum infection is parenteral quinidine gluconate, and that stocking of parenteral quinine dihydrochloride for emergency distribution is no longer required to provide optimal management of P. falciparum infections.
Authors
Journal	MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (MMWR Recomm Rep) Vol. 40 Issue RR-4 Pg. 21-3 (Apr 19 1991) ISSN: 1057-5987 [Print] United States
PMID	1850497 (Publication Type: Guideline, Journal Article)
Chemical References	Antimalarials Quinidine quinidine gluconate
Topics	Animals Antimalarials (administration & dosage) Centers for Disease Control and Prevention, U.S. Emergencies Humans Infusions, Parenteral Malaria (drug therapy) Plasmodium falciparum Quinidine (administration & dosage, analogs & derivatives) United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!